LASIK is safe even in high-risk patients

Article

Long-term follow-up has demonstrated that LASIK is a safe procedure even in high risk, highly myopic eyes.

Long-term follow-up has demonstrated that LASIK is a safe procedure even in high risk, highly myopic eyes, according to Patrick Condon and colleagues from the Waterford Eye Specialists, Dublin, Ireland and the Gordon Binder Vision Centre, USA.

The researchers carried out a postoperative review of 140 eyes of 80 patients who had each undergone LASIK with an ACS microkeratome and broad beam lasers with ablation rate of 12 microns per diopter and intraoperative subtraction pachymetry.

The review showed that, despite the greater risk of developing ectasia after LASIK in highly myopic patients, this normally only occurs in patients with a thicker than anticipated flap resulting in an unacceptable RSB of 120 microns. Therefore, the researchers concluded that LASIK can be considered a safe procedure.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.